Synthetic investigational new drugs for the treatment of tuberculosis.
about
Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status ConsiderationsNew antimycobacterial agents in the pre-clinical phase or beyond: recent advances in patent literature (2001-2016).Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis.Thioridazine: A Non-Antibiotic Drug Highly Effective, in Combination with First Line Anti-Tuberculosis Drugs, against Any Form of Antibiotic Resistance of Mycobacterium tuberculosis Due to Its Multi-Mechanisms of Action.Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline.Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides.
P2860
Synthetic investigational new drugs for the treatment of tuberculosis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Synthetic investigational new drugs for the treatment of tuberculosis.
@en
type
label
Synthetic investigational new drugs for the treatment of tuberculosis.
@en
prefLabel
Synthetic investigational new drugs for the treatment of tuberculosis.
@en
P2860
P1476
Synthetic investigational new drugs for the treatment of tuberculosis.
@en
P2093
Won-Jung Koh
Yong-Soo Kwon
P2860
P304
P356
10.1517/13543784.2016.1121993
P407
P577
2015-11-17T00:00:00Z